Translational Research Initiative
Lead Research Organisation:
University of Glasgow
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The University of Glasgow’s College of Medical, Veterinary and Life Sciences (MVLS) has embedded, and is continuing to develop, impact through identifying, championing and facilitating the translation of highly original novel ideas and concepts across basic underpinning pre-clinical and clinically-facing research in areas that encompass pharmaceuticals, interventions and medical devices. The Translational Research Initiative (TRI) was formed to deliver this vision. Integrated within MVLS’ broader innovation strategy, and aligned with substantial University funding to support dedicated staff, infrastructure and project costs, TRI provides a nexus for translational activities, coordinating access to funding and providing project management support and training for staff through an integrated hub. TRI will continue to actively manage, oversee, distribute and ensure value for money from the Confidence in Concept award. Confidence in Concept funding will be aligned to MVLS strategic priorities and projects, and researchers will be provided with relevant and bespoke opportunities to engage with established industry partners and existing translational infrastructure for advice, training and development of future collaboration. In so doing, TRI will also broaden access to support networks to facilitate academic translational development to areas usually considered to be outside traditional translational funding mechanisms. By capitalising on existing industry and NHS partnerships TRI will ensure basic and clinical researchers are supported from proof of concept through to long term self-funded translational programmes aimed at novel treatments for disease by the development of new therapeutics and diagnostics, TRI is already providing an effective and efficient mechanism for delivery of University of Glasgow and MRC objectives for Confidence in Concept funding and this will be perpetuated by this award.
Organisations
- University of Glasgow (Lead Research Organisation)
- Eccel Technologies (Collaboration)
- Aptamer Group (Collaboration)
- University of California (Collaboration)
- Medicines for Malaria Venture (MMV) (Collaboration)
- Meko (Collaboration)
- NHS Scotland (Collaboration)
- Philips Healthcare (Collaboration)
- Zeus Inc (Collaboration)
- Blanson (Collaboration)
- Bioascent (Collaboration)
- Zeus Scientific (Collaboration)
- University of Dundee (Collaboration)
- Merlin Circuit Tech Ltd (Collaboration)
- LifeArc (Collaboration)
- UNIVERSITY OF GLASGOW (Collaboration)
- University of California, San Diego (UCSD) (Collaboration)
- EnteroBiotix (Collaboration)
- Evotec (UK) Ltd (Collaboration)
- European Lead Factory (Collaboration)
- Altex Technologies Corporation (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- UNIVERSITY OF BRITISH COLUMBIA (Collaboration)
- Vascular Flow Technologies (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
People |
ORCID iD |
Publications
Berkachy R
(2021)
Characterisation of the secreted apyrase family of Heligmosomoides polygyrus.
in International journal for parasitology
Bussooa A
(2020)
Impedimetric Detection and Electromediated Apoptosis of Vascular Smooth Muscle Using Microfabricated Biosensors for Diagnosis and Therapeutic Intervention in Cardiovascular Diseases.
in Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Cook L
(2021)
Induction of stable human FOXP3+ Tregs by a parasite-derived TGF-ß mimic.
in Immunology and cell biology
Crittenden S
(2021)
Prostaglandin E2 promotes intestinal inflammation via inhibiting microbiota-dependent regulatory T cells.
in Science advances
De Beauchamp L
(2022)
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.
in Leukemia
Dickson-Murray E
(2021)
The Mia40/CHCHD4 oxidative folding system: Redox regulation and signalling in the mitochondrial intermembrane space
in Antioxidants
Drurey C
(2020)
Extracellular vesicles: new targets for vaccines against helminth parasites.
in International journal for parasitology
Duque-Correa MA
(2020)
Organoids - New Models for Host-Helminth Interactions.
in Trends in parasitology
Eaglesfield R
(2021)
Targeting and Insertion of Membrane Proteins in Mitochondria.
in Frontiers in cell and developmental biology
| Description | Scientific adviser to Mitochondria Patient Organisations |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.mymitomission.uk/ |
| Description | Bill and Melinda Gates Foundation (BMGF) - AT DNA encoded library screen |
| Amount | $500,000 (USD) |
| Funding ID | INV-003829 |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | |
| Description | Blood Cancer UK - Targeting ERBB signalling in acute myeloid leukaemia |
| Amount | £234,376 (GBP) |
| Funding ID | 1240 |
| Organisation | Blood Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 12/2023 |
| Description | CRUK Programme Foundation Award - Vignir Helgason |
| Amount | £1,345,574 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Development of next generation anti-malarials targeting the essential parasite protein kinase PfCLK3 |
| Amount | £688,273 (GBP) |
| Funding ID | MR/T030569/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 09/2023 |
| Description | Glasgow - Confidence in Concept 2019 |
| Amount | £582,660 (GBP) |
| Funding ID | MC_PC_19039 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2023 |
| Description | Glasgow Knowledge Exchange (GKE) develop wireless antenna vascular graft |
| Amount | £2,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Glasgow Knowledge Exchange Fund |
| Amount | £2,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | John Mercer - VascuStent: Development of therapeutic telemetry |
| Amount | £80,000 (GBP) |
| Organisation | Philips Healthcare |
| Sector | Private |
| Country | Netherlands |
| Start | 08/2022 |
| Description | Preclinical investigation of personalised medicine strategies based on prognostic KDM4A-9 gene signature in AML |
| Amount | £25,000 (GBP) |
| Organisation | Beatson Cancer Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Proximity to Discovery |
| Amount | £5,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 09/2019 |
| Description | Tessa Holyoake Memorial Fund |
| Amount | £5,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | The Howat Foundation - Support grant - Vignir Helgason |
| Amount | £150,000 (GBP) |
| Organisation | The Howard Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Translational Research Initiative |
| Amount | £72,720 (GBP) |
| Funding ID | MC_PC_18048 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 03/2021 |
| Description | University of Glasgow Wellcome Trust Translational Partnership |
| Amount | £800,000 (GBP) |
| Funding ID | 219390/Z/19/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2020 |
| End | 07/2022 |
| Description | UofG Reinvigorating Research Award |
| Amount | £40,000 (GBP) |
| Organisation | University of Glasgow |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 12/2021 |
| Description | Vignir Helgason: Combining TKI Treatment with Novel Autophagy Inhibitor (MRT403) for Eradication of Leukaemic Stem Cells - extension |
| Amount | £182,989 (GBP) |
| Organisation | LifeArc |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2023 |
| End | 04/2024 |
| Title | Protocol for detection of the TRIB2 oncogene in AML cell lines |
| Description | Published the protocol for detection of the TRIB2 oncogene in AML cell lines which was the first objective of the grant proposal funded. The establishment of this methodology now enables the community to use flow cytometry and western blotting to measure the levels of TRIB2 in AML cells. It is in press now in the journal Methods in Enzymology. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | Yes |
| Impact | Other communities can now use flow cytometry and western blotting to measure the levels of TRIB2 in AML cells. |
| Title | AI algorithm for diagnosis cell populations - Vascular Graft |
| Description | Development of Artificial Intelligence (AI) algorithm for discerning different cell populations for diagnosis or cell killing. |
| Type Of Material | Data analysis technique |
| Year Produced | 2021 |
| Provided To Others? | No |
| Impact | N/A |
| Title | Dataset of four key proteins involved in mitochondria biogenesis |
| Description | Dataset of four key proteins involved in mitochondria biogenesis (expression profiles) in over 300 cancer cell lines (in collaboration with EUROFINS). |
| Type Of Material | Database/Collection of data |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | IP generated. |
| Description | Aptamer Group in-kind contribution |
| Organisation | Aptamer Group |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Image based screening of aptamer libraries for novel immunomodulators. Dr. James Brewer's team expanded analysis of enriched aptamer pool. |
| Collaborator Contribution | Costs of aptamer synthesis and labelling have been subsidised by Aptamer Group as an in-kind contribution to the project. |
| Impact | Aptamer analysis pool expanded, toll receptor test completed, formulation optimised. |
| Start Year | 2019 |
| Description | Combining TKI Treatment with Novel Autophagy Inhibitor for Eradication of Leukaemic Stem Cells |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | In development |
| Collaborator Contribution | In development |
| Impact | In development |
| Start Year | 2019 |
| Description | Development of a SMART intravascular biosensor for Cardiovascular disease |
| Organisation | Blanson |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of a intravascular biosensor for cardiovascular disease |
| Collaborator Contribution | Outsourcing of sensor manufacture and encapsulation |
| Impact | In development |
| Start Year | 2019 |
| Description | Development of a SMART intravascular biosensor for Cardiovascular disease |
| Organisation | Eccel Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of intravascular biosensor for cardiovascular disease |
| Collaborator Contribution | Outsourcing of sensor manufacture and encapsulation |
| Impact | In development |
| Start Year | 2019 |
| Description | EnteroBiotix Collaboration - Dr. D. Walker protein antibiotics active against Vancomycin Resistant Enterococcus |
| Organisation | Enterobiotix |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Walkers team identifying, characterising and engineering of highly specific protein antibiotics active against Vancomycin Resistant Enterococcus (VRE) |
| Collaborator Contribution | This project was 50% funded by our industrial partner EnteroBiotix, who provided £33,229 in cash. We have held monthly meetings with EnteroBiotix throughout the project. |
| Impact | Candidates were identified and produced, in vitro activity and stability was successfully tested, leading to accelerated and long term stability testing of the compounds. |
| Start Year | 2019 |
| Description | Image based screening of aptamer libraries for novel immunomodulators |
| Organisation | Aptamer Group |
| Department | Aptamer Solutions |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Novel methodology for screening aptamers |
| Collaborator Contribution | Supply of aptamers for screening |
| Impact | In development |
| Start Year | 2019 |
| Description | Keltic Pharma - European Lead Factory |
| Organisation | European Lead Factory |
| Country | European Union (EU) |
| Sector | Public |
| PI Contribution | Team have now screened 500K compounds against PfCLK3 (Prof. Andrew Tobin). |
| Collaborator Contribution | This project has leveraged £300K in kind funding from the European Lead Factory to progress the project 'Targeting the malaria protein kinase PfCLK3.' |
| Impact | 500K compounds against PfCLK3 have been screened. Paper published 10.1021/acs.jmedchem.0c00451. |
| Start Year | 2020 |
| Description | Keltic Pharma - EvoTec |
| Organisation | Evotec (UK) Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Prof. Andrew Tobin's team at University of Glasgow and Keltic Pharma signed an agreement with EvoTec. The team conducted structural biology based drug design against PfCLK3. |
| Collaborator Contribution | EvoTec contributed in-kind funding of £350K to assist in the drug screening. |
| Impact | 10.1021/acs.jmedchem.0c00451 |
| Start Year | 2020 |
| Description | LifeArc - V. Helgason - Combining TKI Treatment with Novel Autophagy Inhibitor (MRT403) for Eradication of Leukaemic Stem Cells |
| Organisation | LifeArc |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | To test the effect of lead ULK1 inhibitor (MRT403) on survival of leukaemic stem cells using pre-clinical models of Chronic Myeloid Leukaemia. Extra £15k was provided by Helgason to buy mice, when the breeding capacity was restricted due to Covid19 restrictions. |
| Collaborator Contribution | LifeArc supplied the ULK1 inhibitors for the studies. LifeArc undertook manufacture of sufficient quantities of compounds and PK studies to confirm the kinetics and suitability of the compounds for use in humans. LifeArc also provided on-going support in the study with regard to drug development and analysis. |
| Impact | Based on our encouraging results, LifeArc licenced the ULK1 Programme to a Company. The Company has approached Helgason and setup a "Sponsored Collaborative Agreement" for the value of £317,392. This will support the appointment of a Research Assistant/Associate. |
| Start Year | 2019 |
| Description | LifeArc - V. Helgason - Combining TKI Treatment with Novel Autophagy Inhibitor (MRT403) for Eradication of Leukaemic Stem Cells |
| Organisation | University of Glasgow |
| Department | Institute of Cancer Sciences |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | To test the effect of lead ULK1 inhibitor (MRT403) on survival of leukaemic stem cells using pre-clinical models of Chronic Myeloid Leukaemia. Extra £15k was provided by Helgason to buy mice, when the breeding capacity was restricted due to Covid19 restrictions. |
| Collaborator Contribution | LifeArc supplied the ULK1 inhibitors for the studies. LifeArc undertook manufacture of sufficient quantities of compounds and PK studies to confirm the kinetics and suitability of the compounds for use in humans. LifeArc also provided on-going support in the study with regard to drug development and analysis. |
| Impact | Based on our encouraging results, LifeArc licenced the ULK1 Programme to a Company. The Company has approached Helgason and setup a "Sponsored Collaborative Agreement" for the value of £317,392. This will support the appointment of a Research Assistant/Associate. |
| Start Year | 2019 |
| Description | MAISI (King's College London) - VascuGraft: manufacture of active medical devices and implants - JM |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Concept, design and testing of VascuGraft device |
| Collaborator Contribution | Support the development of a human grade device |
| Impact | None yet |
| Start Year | 2022 |
| Description | ML University of British Columbia - VH novel parasite-derived immunosuppressive protein |
| Organisation | University of British Columbia |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Therapeutic application of a novel parasite-derived immunosuppressive protein |
| Collaborator Contribution | Therapeutic application of a novel parasite-derived immunosuppressive protein |
| Impact | Collaboration with University of British Columbia, concluded in 2021 with the publications that year. |
| Start Year | 2020 |
| Description | Medicines for malaria venture - AT |
| Organisation | Medicines for Malaria Venture (MMV) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | CiC funding has also provided the protein for a GHIT screen of 60K molecules |
| Collaborator Contribution | Molecule screening funded by MMV (250K EUROs). |
| Impact | CiC funds have been used to spin out Keltic Pharma Therapeutics Ltd a company with the primary aim of delivering an anti-malarial to the clinic. |
| Start Year | 2019 |
| Description | Philips Healthcare - Therapeutic Graft Development JM |
| Organisation | Philips Healthcare |
| Country | Netherlands |
| Sector | Private |
| PI Contribution | Graft and therapeutic development. |
| Collaborator Contribution | New contract with Philips Healthcare @~90K FEC to develop the therapeutic aspects of the device. |
| Impact | N/A. Multidisciplinary - Engineering, Bioelectronics, Cardiovascular & Medical Sciences. |
| Start Year | 2021 |
| Description | SM University of California San Diego - VH novel parasite-derived immunosuppressive protein |
| Organisation | University of California, San Diego (UCSD) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Therapeutic application of a novel parasite-derived immunosuppressive protein |
| Collaborator Contribution | Therapeutic application of a novel parasite-derived immunosuppressive protein |
| Impact | Concluded in 2021 with publication in that year. |
| Start Year | 2020 |
| Description | Smart Stent - Meko Inc |
| Organisation | Meko |
| Country | Germany |
| Sector | Private |
| PI Contribution | Development of a SMART intravascular biosensor for Cardiovascular disease; design, fabricate and test a working prototype device by transitioning our 2D sensor onto a flexible substrate. |
| Collaborator Contribution | Aiding in the manufacturing of medical devices. Dr. J. Mercer partnered with Meko Inc and moved from a purely 3D printed design to a mass producible custom stent and custom graft that incorporates a new sensor platform. |
| Impact | The sensor and graft approach was identified as optimal as advances in the telemetry package can be included extravascularly, this make surgical deployment realistic and helped us identify AVGrafts as the best device class. Work still ongoing. |
| Start Year | 2020 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Altex Technologies Corporation |
| Country | United States |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Blanson |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Eccel Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Meko |
| Country | Germany |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Smart Stent Commercial Collaborators |
| Organisation | Zeus Scientific |
| Country | United States |
| Sector | Private |
| PI Contribution | Mercers group fabricated flexible sensors for the stent device, incorporated the sensor onto the device prototype and developed a telemetry system and software with a iOS/android interface to link the device to a handheld device. |
| Collaborator Contribution | All partners aid in the future refinement of the project. In 2020 both Alter, Meko and Zeus were able to produce scalable product for Mercer and continue to develop required post processing steps. After successful trials, Meko Inc. mass produced the custom stents. |
| Impact | Scalable device now made. Gained the support of 2 additional clinicians with an interest in this area to ensure the compliance and direction of the work. Clinical advisor group formalised. Designed bespoke AI algorithms to aid the measurement analysis from the sensor. |
| Start Year | 2019 |
| Description | Targeting the malaria protein kinase PfCLK3 |
| Organisation | BioAscent |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Development of new assay |
| Collaborator Contribution | Screening of compound collection |
| Impact | In development |
| Start Year | 2019 |
| Description | University of Glasgow - University of Edinburgh Smart Stent |
| Organisation | University of Edinburgh |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University of Glasgow supported this project with £10K of funds to support Dr. J. Mercer's (UofG) project to develop a SMART intravascular biosensor for Cardiovascular disease to aid in the design, fabrication and testing of a working prototype device. |
| Collaborator Contribution | The University of Edinburgh also provided ~£65K to part fund the 2xPDRA who worked on this project. |
| Impact | Further funding from the Glasgow Knowledge Exchange fund was awarded. Industry collaborations were established to manufacture the devices at a larger scale. |
| Start Year | 2020 |
| Description | University of Glasgow - University of Edinburgh Smart Stent |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University of Glasgow supported this project with £10K of funds to support Dr. J. Mercer's (UofG) project to develop a SMART intravascular biosensor for Cardiovascular disease to aid in the design, fabrication and testing of a working prototype device. |
| Collaborator Contribution | The University of Edinburgh also provided ~£65K to part fund the 2xPDRA who worked on this project. |
| Impact | Further funding from the Glasgow Knowledge Exchange fund was awarded. Industry collaborations were established to manufacture the devices at a larger scale. |
| Start Year | 2020 |
| Description | University of Glasgow and University of Dundee - Keltic Pharma |
| Organisation | Medicines for Malaria Venture (MMV) |
| Country | Switzerland |
| Sector | Charity/Non Profit |
| PI Contribution | Prof. Andrew Tobins lab (University of Glasgow) collaborated in project entitled 'Targeting the malaria protein kinase PfCLK3.' the team have strong evidence that targeting PfCLK3 will result in rapid parasite killing at multiple parasite life cycle stages including asexual and sexual stages as well as delivering parasiticidal activity at more than one species of human malaria. As such their data points to inhibitors of PfCLK3 being effective for the symptomatic treatment and blocking transmission of malaria. |
| Collaborator Contribution | The primary partners are the Medicines for Malaria Venture who have provided a letter in support for our work (provided to satisfy referees concerns during the Science paper submission) that states that the tool compounds meet their criteria for further development. Their aim is for MMV to support development of our PfCLK3 inhibitors in partnership with the DDU and Glasgow. They also wish to pursue the PfCLK3 inhibitor development with Elizabeth Winzeler at Skaggs School of Pharmaceutical Sciences, University of California, San Diego, a strong supporter and co-author on the Science paper: 10.1101/404459. |
| Impact | Paper 10.1101/404459. £300K in kind funding from the European Lead Factory and agreement with EvoTec for in-kind funding of £350K as well as the establishment of a spin out biotech company called Keltic Pharma Therapeutics Ltd. |
| Start Year | 2019 |
| Description | University of Glasgow and University of Dundee - Keltic Pharma |
| Organisation | University of California |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Prof. Andrew Tobins lab (University of Glasgow) collaborated in project entitled 'Targeting the malaria protein kinase PfCLK3.' the team have strong evidence that targeting PfCLK3 will result in rapid parasite killing at multiple parasite life cycle stages including asexual and sexual stages as well as delivering parasiticidal activity at more than one species of human malaria. As such their data points to inhibitors of PfCLK3 being effective for the symptomatic treatment and blocking transmission of malaria. |
| Collaborator Contribution | The primary partners are the Medicines for Malaria Venture who have provided a letter in support for our work (provided to satisfy referees concerns during the Science paper submission) that states that the tool compounds meet their criteria for further development. Their aim is for MMV to support development of our PfCLK3 inhibitors in partnership with the DDU and Glasgow. They also wish to pursue the PfCLK3 inhibitor development with Elizabeth Winzeler at Skaggs School of Pharmaceutical Sciences, University of California, San Diego, a strong supporter and co-author on the Science paper: 10.1101/404459. |
| Impact | Paper 10.1101/404459. £300K in kind funding from the European Lead Factory and agreement with EvoTec for in-kind funding of £350K as well as the establishment of a spin out biotech company called Keltic Pharma Therapeutics Ltd. |
| Start Year | 2019 |
| Description | University of Glasgow and University of Dundee - Keltic Pharma |
| Organisation | University of Dundee |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Prof. Andrew Tobins lab (University of Glasgow) collaborated in project entitled 'Targeting the malaria protein kinase PfCLK3.' the team have strong evidence that targeting PfCLK3 will result in rapid parasite killing at multiple parasite life cycle stages including asexual and sexual stages as well as delivering parasiticidal activity at more than one species of human malaria. As such their data points to inhibitors of PfCLK3 being effective for the symptomatic treatment and blocking transmission of malaria. |
| Collaborator Contribution | The primary partners are the Medicines for Malaria Venture who have provided a letter in support for our work (provided to satisfy referees concerns during the Science paper submission) that states that the tool compounds meet their criteria for further development. Their aim is for MMV to support development of our PfCLK3 inhibitors in partnership with the DDU and Glasgow. They also wish to pursue the PfCLK3 inhibitor development with Elizabeth Winzeler at Skaggs School of Pharmaceutical Sciences, University of California, San Diego, a strong supporter and co-author on the Science paper: 10.1101/404459. |
| Impact | Paper 10.1101/404459. £300K in kind funding from the European Lead Factory and agreement with EvoTec for in-kind funding of £350K as well as the establishment of a spin out biotech company called Keltic Pharma Therapeutics Ltd. |
| Start Year | 2019 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Eccel Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Merlin Circuit Tech Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | NHS Scotland |
| Department | NHS 24 |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Vascular Flow Technologies |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Description | VascuSens Graft Development - JM Stent Custom Graft Fabrication |
| Organisation | Zeus Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | UofG Reinvigorating Research Award, Wellcome and MRC funding utilised to develop graft technology; three researchers in UofG supported and working on graft and sensor development. |
| Collaborator Contribution | 1) Zeus Inc - contract service for custom graft fabrication and regular supply of samples and service to the value or £2000. 2) Vascular flow Ltd - contract services and collaborator on sensor encapsulation and Arran Biomedical Ltd for secondary processing. 3) Merlin Ltd - contract service from sensor array design and fabrication 4) NHS - lead clinical advisor and lead surgeon on porcine trial 5) Eccel Technologies Ltd - contract service for custom PCB and encapsulation design service in kind to the value of £2000. |
| Impact | Follow on funding awarded. Multidisciplinary: UofG School of Engineering, College of Medical, Veterinary and Life Sciences Bioelectronics Unit. |
| Start Year | 2020 |
| Title | MATERIALS AND METHODS FOR INDUCING REGULATORY T CELLS |
| Description | The present invention concerns a structurally distinct immunosuppressive mimic of TGF-ß that is a potent inducer of murine and human regulatory T cells and provides a therapeutic agent for the treatment of inflammatory disorders. Disclosed herein is a novel parasite TGF-ß mimic which fully replicates the biological and functional properties of TGF-ß, including binding to mammalian TGF-ß receptors and inducing Foxp3+ Treg in both murine and human CD4+ T cells. This TGF-ß mimic shares no homology to mammalian TGF-ß or other members of the TGF-ß family, but is distantly related to the complement control protein (CCP) superfamily. |
| IP Reference | GB1712556.8A |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | In development |
| Title | MATERIALS AND METHODS FOR INDUCING REGULATORY T CELLS |
| Description | The present invention concerns a structurally distinct immunosuppressive mimic of TGF-ß that is a potent inducer of murine and human regulatory T cells and provides a therapeutic agent for the treatment of inflammatory disorders. Disclosed herein is a novel parasite TGF-ß mimic which fully replicates the biological and functional properties of TGF-ß, including binding to mammalian TGF-ß receptors and inducing Foxp3+ Treg in both murine and human CD4+ T cells. This TGF-ß mimic shares no homology to mammalian TGF-ß or other members of the TGF-ß family, but is distantly related to the complement control protein (CCP) superfamily. |
| IP Reference | WO2019025621 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | In development |
| Title | App software for vascular data |
| Description | iOS/Android App software for wireless interrogation of data sets. |
| Type Of Technology | Webtool/Application |
| Year Produced | 2022 |
| Impact | N/A |
| Company Name | KELTIC PHARMA LIMITED |
| Description | Biotech company aims to deliver an novel anti-malarial to the clinic in five years that targets PfCLK3. |
| Year Established | 2021 |
| Impact | Not currently applicable. |
| Company Name | GLOX THERAPEUTICS LIMITED |
| Description | Incorporated on 27 February 2023; Research and experimental development on biotechnology; Other research and experimental development on natural sciences and engineering |
| Year Established | 2023 |
| Impact | None yet |
| Description | Prof. Kostas Tokatlidis - Lily Foundation family weekend |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | PPIE (Public patient involevement and engagement): Prof Tokatlidis was invited as a speaker in the Lily Foundation family weekend (the largest UK based mito-patient charity) alongside the RA Fara van der Schans. Prof Tokatlidis led 2 focused workshops in the meeting and Fara van der Schans another one. Disemination after this on social media channels (twitter of Tokatlidis Lab and the Lily Foundation); https://www.youtube.com/watch?v=mmAyUv30zPI ; https://www.youtube.com/watch?v=ejQaeEqDn7Y |
| Year(s) Of Engagement Activity | 2020,2021 |
| URL | https://www.youtube.com/watch?v=mmAyUv30zPI |
| Description | Prof. Kostas Tokatlidis - Mitotargin case study video |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Prof Kostas Tokatlidis (Cathcart Chair of Biochemistry, University of Glasgow) and Dr Keith Wreggett (Biotech Consultant, InnoSpective) discuss the Mitotargin Project; an innovative translational project to develop therapeutic and diagnostic applications through research into the mitochondria. Mitotargin Translational Project funded through the Wellcome Trust Translational Partnership Award, grant ref. 219390/Z/19/Z, BBSRC Impact Accelerator Account ref. BB/S506734/1, MRC Proximity to Discovery award ref. MC_PC_17190 and MRC Confidence in Concept Award, grant ref. MC_PC_18048 and MC_PC_19039. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=1YJLB1nVnO4 |